BioTrackTHC, A Subsidiary Of Helix TCS Inc (OTCMKTS:HLIX), And I Heart Jane Agree to Integrate For Delivery Enablement And Turnkey Content Generation To Dispensaries

BioTrackTHC, a subsidiary of Helix TCS Inc (OTCMKTS:HLIX), and I Heart Jane, have entered a pact to integrate their technology platforms. As per the terms of the deal, the seed to sale tracking and dispensary point of sale software of BioTrackTHC will be integrated with e-commerce software of I Heart to provide an improved retail experience.

Turnkey content generation for dispensaries

Following the integration, over 2,000 customer locations of BioTrackTHC will be integrated with the e-commerce platform of I Heart to offer customer insights, delivery enablement, and turnkey content generation services to dispensaries.

The customers of BioTrackTHC POS can enjoy customizable and easy to use ordering platform. BioTrackTHC integration with I Heart allows the retailers to show product pricing and availability in real-time. Now the customers can choose their favorite branded products from the local dispensaries.

Chief Operating Officer of BioTrackTHC, Moe Afaneh, said the retail operators are developing an easy to use and best in class technology systems to improve brand recognition and stay apart. Its customers can choose from a host of integrated technologies and customize to suit their needs.

Chief Executive Officer of I Heart, Socrates Rosenfeld, said the cannabis industry is offering the best technologies for the retail world. The integration of the two technology platforms of I Heart And BioTrackTHC automates online ordering. Offline retailers can use this software to connect with the products in the physical store or direct them to a delivery hub in a nearby location for local shoppers.

Continues to meet the targets

Chief Executive Officer and Executive Chairman of Helix, Zachary L. Venegas, said the company is continuing to meet set targets on key initiatives in Q3 2019. Internal improvements, strong focus on customer service, and strategic acquisitions are helping the company to drive growth and improve shareholder value. It has adopted cost-saving measures and improved the cash flow to realize profits.

Helix has posted revenues of $3.74 million (up 20%) in Q3 2019. The company completed the takeover of Amercanex in Q3 2019. It undertook several development initiatives to post robust revenues in Q4 2019. The company processed cannabis sales worth more than $20 billion. Commercial booking of BioTrackTHC increased to $489,000 (up 27%).